BRII-297 / Brii Biosci - LARVOL DELTA

A Study of BRII-297 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: Brii Biosciences Limited | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

A Study of BRII-297 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Brii Biosciences Limited | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders (PRNewswire) - "Brii Biosciences Limited...announced the first subject has been dosed in a Phase 1 clinical trial evaluating BRII-297, a first-of-its-kind long-acting injectable (LAI), in development for the treatment of various anxiety and depressive disorders. This Phase 1 study is examining the safety, tolerability and pharmacokinetics of BRII-297 in healthy volunteers in Australia."

Trial status • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry • Women's Health

A Study of BRII-297 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: Brii Biosciences Limited

New P1 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry